Premium
THE INTERACTION OF HUMAN PANCREATIC GROWTH HORMONE RELEASING FACTOR 1–44 WITH SOMATOSTATIN IN VIVO IN NORMAL MAN
Author(s) -
DAVIES R. R.,
TURNER S. J.,
ØRSKOV H.,
JOHNSTON D. G.
Publication year - 1985
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1985.tb00223.x
Subject(s) - somatostatin , endocrinology , medicine , in vivo , growth hormone , somatropin , peptide hormone , hormone , chemistry , biology , microbiology and biotechnology
SUMMARY The interaction between the stimulatory effects of hpGRF 1–44 and the inhibitory effects of somatostatin on GH release have been investigated in six normal male subjects receiving continuous 4 h infusions of these peptides alone and in combination. hpGRF 1–44 0·3 μg/kg/h alone produced a peak GH response of 27·0 ± 7·6 mU/1 (mean ± SEM). Somatostatin 1·0 μg/kg/h markedly inhibited the GH response to hpGRF 1–44 with mean levels > 4·0 mU/1 during the infusion, though a rebound rise in GH levels to 26·1 ± 9·0 mU/1 was observed at the end of the infusion period. Somatostatin 0·2 μg/kg/h inhibited the GH response to hpGRF 1–44 to a lesser degree (peak GH during the infusion 11·7 ± 2·5 mU/1) and the rebound rise in GH levels (maximum 13·2 ± 4·3 mU/1) was less than that observed with high dose somatostatin. During somatostatin 1·0 μg/kg/h alone GH levels were suppressed > 1·0 mU/1 followed by a rebound at the end of the infusion in only two subjects. These data demonstrate a dose‐dependent inhibition of hpGRF 1–44 by somatostatin in vivo in man.